Summary
Unable to perform an audit against the supplied FDA-approved label because the provided label is for isosorbide dinitrate oral tablets (ISDN), while the AI claims repeatedly refer to isosorbide mononitrate and to strengths/formulations (e.g., 60 mg) that are not evidenced in the provided ISDN label excerpt. As a result, label support/contradiction cannot be reliably established.
Category Scores
Accurate Statements
None can be confirmed as accurately supported by the provided labeling excerpts because the AI response targets isosorbide mononitrate (ISMN), while the supplied prescribing information is for isosorbide dinitrate oral tablets (ISDN).
Unable to map claims to label text due to active-ingredient mismatch.
Unsupported Statements
“Isosorbide mononitrate is an anti-anginal medicine used to prevent chest pain (angina) caused by reduced blood flow to the heart.”
The provided label excerpts are for isosorbide dinitrate oral tablets (ISDN), not isosorbide mononitrate. No provided label text supports statements about isosorbide mononitrate.
“A 60 mg dose of isosorbide mononitrate is typically used as an oral maintenance dose taken on a schedule rather than to treat sudden angina attacks.”
The provided label excerpt lists ISDN dosing ranges (e.g., maintenance 10 mg to 40 mg, two or three times daily) and discusses prevention vs aborting acute episodes for ISDN. The AI claim uses 60 mg and specifies isosorbide mononitrate, neither of which is supported by the provided ISDN label excerpts.
“The dosing and timing … depend on the exact product’s release type (extended-release/once-daily versus other formulations).”
The provided label excerpt discusses daily dose-free interval requirements for immediate-release ISDN and mentions once-daily regimens, but it is not evidence for isosorbide mononitrate or for the specific release-type framing used by the AI.
“Isosorbide mononitrate is generally taken consistently at the prescribed times and not as needed for immediate relief.”
Although the provided label states immediate-release ISDN onset is not sufficiently rapid to abort an acute episode (supporting prevention rather than aborting), the AI statement is about isosorbide mononitrate and uses broad “generally” language not supported for mononitrate.
“Most ‘60 mg’ strengths … are commonly associated with long-acting formulations.”
The provided label excerpts do not discuss 60 mg strengths or any mapping of mononitrate strengths to release types.
“Strength alone doesn’t confirm the release type …”
No provided label excerpt supports this generalization.
“Common side effects … can include headache/dizziness/flushing/low blood pressure.”
The provided label excerpt supports headache and transient lightheadedness and mentions hypotension/syncope. It does not mention flushing. Also, these adverse-effect claims are attributed to isosorbide mononitrate, while the label excerpts are for isosorbide dinitrate.
“Because nitrates can lower blood pressure, some people feel lightheaded when standing … especially when starting therapy or when the dose increases.”
The ISDN label excerpt supports severe hypotension, particularly with upright posture, and transient lightheadedness, but it is not provided in connection with isosorbide mononitrate or with the AI’s “starting therapy or when the dose increases” causal emphasis; thus not fully supported as stated.
“The most important interaction … is with erectile dysfunction medicines that are commonly sildenafil, tadalafil, and vardenafil.”
The provided label excerpt explicitly discusses sildenafil interaction. It does not mention tadalafil or vardenafil in the provided interaction text.
“Using sildenafil, tadalafil, or vardenafil with isosorbide mononitrate can cause dangerous drops in blood pressure.”
The provided label excerpt supports severe hypotension with sildenafil plus ISDN. It does not provide equivalent support for tadalafil or vardenafil, and the claim is for isosorbide mononitrate rather than ISDN.
“Patients should be cautious with other blood-pressure–lowering medicines when taking isosorbide mononitrate.”
The provided label excerpt states additive vasodilator effects and mentions alcohol specifically; it does not provide the broad instruction about “other blood-pressure–lowering medicines” as stated for mononitrate.
“Patients should seek urgent care if they have symptoms like fainting / severe dizziness.”
The provided label excerpt reports syncope and lightheadedness as possible adverse reactions but does not include patient-facing “urgent care” instructions.
“Patients should seek urgent care if they have chest pain that does not improve as directed by a clinician.”
The provided label excerpt does not include this guidance for chest pain management.
“If a patient misses a dose … they typically take it when they remember unless it’s close to the next scheduled dose.”
The provided label excerpts do not include missed-dose instructions.
“Isosorbide mononitrate (such as long-acting forms) is usually for prevention rather than immediate symptom relief during an acute angina episode.”
The provided label excerpt supports ISDN prevention and notes immediate-release oral ISDN is not sufficiently rapid for aborting acute episodes, but it is not evidence for isosorbide mononitrate or specifically for “long-acting forms” language.
“Short-acting nitrate sprays or tablets are often used for immediate symptom relief during an acute angina episode.”
The provided label excerpts for ISDN do not discuss nitrate sprays or short-acting nitrate tablets as commonly used for acute episodes.
Contradictions
Low
AI Statement
No direct contradiction can be identified with certainty because the supplied label excerpts do not mention isosorbide mononitrate, 60 mg strengths for mononitrate, tadalafil/vardenafil interactions, or the specific patient-facing “urgent care” instructions.
Label Reference
Not determinable from provided label excerpts due to active-ingredient mismatch.
Important Omissions
The AI response does not align its content with the provided label’s critical prevention/tolerance statements for ISDN, including the requirement for a daily dose-free interval and the label’s explicit note that immediate-release ISDN onset is not sufficiently rapid to abort acute angina.
Importance:
Moderate
The AI response omits key ISDN safety/treatment guidance present in the provided label excerpt for sildenafil interaction (treat as nitrate overdose, supportive care description) and other warning details not replicated.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Potential risk is elevated because claims about drug identity (mononitrate vs the provided ISDN label), dosing strength (60 mg), and interactions (includes tadalafil/vardenafil though label excerpt only mentions sildenafil) are not supported by the supplied prescribing information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Active ingredient/label mismatch (isosorbide mononitrate claimed vs label isosorbide dinitrate ISDN); additional unsupported specifics (60 mg dosing, tadalafil/vardenafil interaction, flushing, urgent care/missed-dose guidance).
Suggested Improvement
Re-write claims to refer to the same product as the provided label (isosorbide dinitrate oral tablets), restrict interaction statements to those explicitly included (sildenafil in provided excerpt), and use only dosing/adverse-reaction information present in the supplied ISDN label text (avoid adding unsupported strengths, release-type generalizations, or patient-action instructions not present in the label).